Philips Healthcare parent Royal Philips has received clearance from the U.S. Food and Drug Administration (FDA) for its SmartCT 3D image acquisition, visualization, and measurement software, which is a key part of its Azurion image-guided therapy system.
SmartCT produces CT-like 3D images that support diagnosis of disease, therapy planning, and treatment follow-up for interventional radiology procedures. It consists of a touch-screen tablet and can be used for angiography, neurology, soft-tissue imaging, and guidewire/catheter navigation, the company said.
SmartCT includes a table-side touchscreen control that offers interventionalists enhanced diagnostic confidence and streamlined workflows. Image courtesy of Philips Healthcare.SmartCT guides users through the process of image acquisition, and clinicians can review and interact with images using a table-side touchscreen module and 3D visualization and measurement tools. The tools include features like distance measurements on 3D images, the ability to remove structures obstructing regions of interest, and the ability to select and store optimum projection angles for recall during procedures.
